The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy

Transfusion and Apheresis Science

Volumn 30, Issue 1, 2004, Pages 9-15

  Arat, Mutlu ^a   Arslan, Önder ^a   Gürman, Günhan ^a   Dalva, Klara ^b   Özcan, Muhit ^a   Uǧur, Aynur ^c   Ilhan, Osman ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Hematodiagnostic Laboratory   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

Author keywords

CD3 positive cells; CD34 positive cells; Donor lymphocyte infusion (DLI); G CSF (filgrastim); Lymphocyte apheresis

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BLOOD DONOR; BLOOD VOLUME; BODY WEIGHT; CELL SEPARATION; CELL SUBPOPULATION; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MALE; NORMAL HUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; T LYMPHOCYTE; TARGET CELL;

EID: 1642436454     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2003.05.004     Document Type: Article

References (23)

1. Alyea E. Adoptive immunotherapy insights from donor lymphocyte infusions. Transfusion. 40:2000;393.
2. MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br. J. Haematol. 110:2000;12-17.
3. Faber L.M., van der Hoeven J., Goulmy E., Hooftman-den Otter A.L., van Luxemburg-Heijs S.A., Willemze R.et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest. 96:1995;877-883.
4. Jiang Y.Z., Mavroudis D., Dermime S., Hensel N., Couriel D., Molldrem J.et al. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br. J. Haematol. 93:1996;606-612.
5. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
6. Gürman G. Donor leukocyte infusion for the treatment of leukemia relapse after allogeneic hemapoietic cell transplantation with myeloablative conditioning. Turk. J. Haematol. 17:2000;171-181.
7. Slavin S., Morecki S., Weiss L., Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and non-malignant diseases in conjuction with allogeneic stem cell transplantation. J. Hematother. Stem. Cell. Res. 11:2002;265-276.
8. Roush K.S., Hillyer C.D. Donor lymphocyte infusion therapy. Transfus. Med. Rev. 16(2):2002;161-176.
9. Papadopoulos E.B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M.H.et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1994;1185-1191.
10. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D.et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044.
11. Gürman G., Arat M., Ilhan O., Konuk N., Beksaç M., Çelebi H.et al. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy. 3:2001;253-260.
12. Demirer T., Ilhan O., Arat M., Genç I., Özcan M., Dalva K.et al. CD41+ and CD42+ hematopoietic cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation. J. Clin. Apheresis. 16:2001;67-73.
13. Sato H., Shiobara S., Yasue S., Chuhjo T., Nakao S. Lymphocyte collection for donor leukocyte infusion form normal donors: estimation of the minimum processed blood volume and safety of the procedure. Vox Sang. 81:2001;124-127.
14. Sica S., Di Mario A., Salutari P., Rutella S., Chiusolo P., Rumi C.et al. Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 16(3):1995;483-485.
15. Levine J.E., Braun T., Penza S.L., Beatty P., Cornetta K., Martino R.et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J. Clin. Oncol. 20(2):2002;405-412.
16. Sohn S.K., Jung J.T., Kim D.H., Lee N.Y., Seo K.W., Chae Y.S.et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer. 94(1):2002;18-24.
17. Flower M.E., Leisenring W., Beach K., Riddell S., Radich J.P., Higano C.S.et al. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol. Blood Marrow Transplant. 6:2000;321-326.
18. Keil F., Haas O.A., Fritsch G., Kahls P., Lechner K., Mannhalter C.et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood. 89:1997;3113-3117.
19. Dazzi F., Syzdlo M., Craddock C., Cross C.P., Kaeda J., Chase A.et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 95:2000;67-71.
20. Anderlini P., Przepiorka D., Huh Y., Lauppe J., Miller P., Sundberg J.et al. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Brit. J. Haematol. 93:1996;940-942.
21. Engelhardt M., Bertz H., Afting M., Waller C.F., Finke J. High versus standard dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J. Clin. Oncol. 17:1999;2160-2172.
22. Körbling M., Giralt S., Khouri I., Mirza N., Donato M., Anderlini P.et al. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J. Clin. Apheresis. 16:2001;82-87.
23. Nakamura R., Bahceci E., Read E.J., Leitman S.F., Carter C.S., Childs R.et al. Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell - depleted peripheral blood stem cell transplants with delayed lymphocyte add-back. Brit. J. Haematol. 115:2001;95-104.